Steven Dodson

Steve Dodson comes to CODA with deep expertise in the discovery and early development of small molecule therapeutics targeting ion channels. Prior to joining CODA, Steve served as Senior Director, Drug Discovery and Development at Second Genome, Inc. where he was responsible for the advancement of the SGM-1019 program through Phase I for the treatment of Nonalcoholic Steatohepatitis. Previously he held positions of increasing responsibility at NeuroTherapeutics Pharma, Inc., and Renovis, Inc., where his work focused on the discovery and development of small molecule therapeutics to treat pain, central nervous system disorders and inflammation. He is also a cofounder of Myotherix, Inc. a company focused on discovering and developing novel therapeutics for the treatment of degenerative muscle disorders through the modulation of calcium handling.

Steve received his Ph.D. in biological sciences from Stanford University and a B.S. in genetics from University of California, Berkeley.